You are here
IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENCE IN LT HCV/HIV COINFECTION
Christian Manzardo1, Maria Carlota Londoño1, Ana Moreno2, Lluis Castells3, Victoria Aguilera4, Jose R. Fernandez5, Jorge Calvo-Pulido6, Judith Peñafiel1, Antoni Rimola1, Jose M. Miro1
1Univ of Barcelona, Barcelona, Spain,2Hosp Ramon y Cajal, Madrid, Spain,3Hosp Univ Vall d‘Hebron, Barcelona, Spain,4Hosp Univ La Fe, Valencia, Spain,5Hosp Univ de Cruces, Barkaldo, Spain,6Hosp 12 de Octubre, Madrid, Spain
Interferon (IFN)-based therapy against hepatitis C virus (HCV) recurrence after liver transplantation (LT) has poor effectiveness and tolerability both in HCV-mono-infected (≈30% of sustained virological response [SVR]) and HIV-HCV co-infected LT recipients (≈20% of SVR). Only small case series have reported on the use of direct antiviral agents (DAAs) in LT HCV/HIV co-infected recipients. The aim of this study is to report the effectiveness and safety of IFN-free regimens in a nationwide cohort of HIV HCV co-infected individuals having undergone LT.
A prospective, multicenter cohort study, including HCV/HIV co-infected LT patients who received IFN-free treatment for recurrent hepatitis C with two or more DAAs (patients receiving DAAs with IFN or Sofosbuvir (SOF) plus ribavirine (RBV) were excluded). For comparison, we included a matched cohort of HCV mono-infected patients who received similar treatment for recurrent HCV. Only patients reaching a follow-up of at least 12 weeks after the end of treatment were analyzed.
Among patients with post-LT HCV recurrence in the FIPSE cohort, 39/228 (17%) of HIV+ and 118/693 (17%) of HCV mono-infected patients received IFN-free regimens containing at least 2 DAAs +/- RBV after a median (IQR) of 42 (16-72) months after LT. No differences in demographics and pre- or peri-transplant characteristics were observed. For HIV-infected individuals, median (IQR) CD4 T-cell count was 367 (200-465) cells/µL. All patients received antiretroviral treatment (ART) and 33 (85%) had a plasma HIV-RNA <50 copies/mL; 19 (48%) were receiving ART based on a non-boosted integrase inhibitor. SVR rates were high (95%) and similar in the HIV-infected and uninfected cohorts (Table). Of note, two failures in HIV+ patients were observed for genotype 4 (SVR 75% vs. 100% among other genotypes, p=0.038). No significant differences in SVR rates among genotypes were observed for HCV mono-infected individuals. Treatment was well tolerated. Only one patient in the mono-infected cohort died because treatment was started in the advanced decompensated cirrhosis stage.
IFN-free regimens for post LT HCV recurrence in HIV infected individuals of our national cohort were highly effective and well tolerated, with results comparable to HCV mono-infected patients. Newer treatment options will probably improve efficacy for genotype 4 in co-infected LT recipients.